Video Experimental Relacionado
Updated: Sep 9, 2025
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
374
Falta de asociación entre tumores malignos anteriores o concurrentes y la supervivencia global en el cáncer
Hannah C Puhr1,2, Luzia Berchtold1,3, Linda Zingerle1,2
1Department of Medicine I, Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Resumen
Los sobrevivientes de cáncer con antecedentes de otras neoplasias son comunes en los casos de cáncer gastroesofágico. Este historial no afectó a la supervivencia general, lo que sugiere una inclusión más amplia en ensayos clínicos.
Área de la Ciencia:
- En el campo de la oncología
- Investigación sobre la supervivencia al cáncer
- Eligibilidad para ensayos clínicos
Sus antecedentes:
- Los antecedentes de tumores malignos previos o concurrentes son un criterio de exclusión frecuente en los ensayos clínicos de cáncer.
- Existen datos limitados sobre el impacto de la supervivencia al cáncer en los resultados en pacientes con cáncer gastroesofágico.
Objetivo del estudio:
- Investigar la asociación entre los antecedentes de otras neoplasias y las características del paciente/tumor y la supervivencia global en pacientes con cáncer gastroesofágico.
- Informar los criterios de elegibilidad para ensayos clínicos en los que participen sobrevivientes de cáncer gastroesofágico.
Principales métodos:
- Análisis retrospectivo de 1491 pacientes con cáncer gastroesofágico tratados en la Universidad Médica de Viena.
- Examen de tumores malignos anteriores o concurrentes autoinformados en relación con las características del paciente, las características del tumor, los síntomas y la supervivencia general (SO).
Principales resultados:
- El 18% de los pacientes tenían antecedentes de otros diagnósticos de cáncer primario.
- Los antecedentes de otras neoplasias se asociaron con la edad avanzada, la histología de células escamosas, las etapas de tumor localizado menos agresivas y menos síntomas de reflujo ácido.
- No se encontró una asociación estadísticamente significativa entre los antecedentes de otras neoplasias y la supervivencia global.
Conclusiones:
- Los antecedentes de otras enfermedades malignas son frecuentes en pacientes con cáncer gastroesofágico y no afectan negativamente a la supervivencia general.
- Los supervivientes de cáncer no deben ser excluidos categóricamente de los ensayos clínicos por su condición de supervivientes.
- Se necesita más investigación prospectiva para optimizar los criterios de elegibilidad de los sobrevivientes de cáncer en ensayos clínicos.
Videos de Conceptos Relacionados
01:21Barrett Esophagus-II: Clinical Manifestations and Management
292
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
292
01:21Cancer Survival Analysis
448
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
448
01:21Barrett Esophagus-I: Introduction
198
Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
198
01:30Esophageal Strictures-I: Introduction
264
Esophageal strictures involve abnormal narrowing or tightening of the esophagus. They vary in length and severity, ranging from mild constriction to complete obstruction, and are classified as benign (noncancerous) or malignant (cancerous).
Etiology
The primary cause of esophageal strictures is long-standing gastroesophageal reflux disease (GERD), accounting for about 70 to 80% of adult cases. Chronic acid reflux can lead to injury and scarring of the esophageal lining, culminating in...
Etiology
The primary cause of esophageal strictures is long-standing gastroesophageal reflux disease (GERD), accounting for about 70 to 80% of adult cases. Chronic acid reflux can lead to injury and scarring of the esophageal lining, culminating in...
264
02:07Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K